Newsroom

Adherence to treatment plans is essential to optimize clinical outcomes for patients with chronic conditions.  SPUR is a unique adherence solution that provides an individual behavioral diagnosis and intervention plan for each patient.

Integration addresses critical need for accurate, real-time automated insulin delivery data in Type 1 Diabetes clinical research

Members from multiple therapeutic areas will incorporate the patient voice into clinical trial technology design.

Industry-leading behavioral science tool SPUR™ is validated to predict adherence and will be offered through the Clinical ink technology platform

Clinical ink, a global life science technology company, announces the promotion of John Pappadakis from EVP, Global Business Development to Chief Commercial Officer and Megan Petrylak from EVP, Clinical Operations to Chief Operating Officer.

Clinical ink announces EDCXtra: An integrated web-based EDC, DDC and eCOA platform.

Scroll to Top

Contact Clinical ink

Request more information, submit questions, set up a demonstration, and more.